A High Court bench has declined to issue a stay order against Dr Reddy's Laboratories ' export of semaglutide to certain international markets. The court's refusal to grant the stay allows the pharmaceutical major to continue its overseas sales operations of the important diabetes and weight management medication.

Court Decision Impact

The High Court's decision represents a significant development for Dr Reddy's international business operations. By refusing to halt the export activities, the court has effectively permitted the company to maintain its supply chain and commercial commitments to international markets.

Semaglutide Market Significance

Semaglutide is a crucial medication used in the treatment of diabetes and weight management. The drug has gained significant importance in global pharmaceutical markets due to its therapeutic benefits and growing demand among patients worldwide.

Business Operations Continuity

The court's ruling ensures that Dr Reddy's Laboratories can maintain its export operations without legal interruption. This decision supports the company's ability to fulfill existing international contracts and continue serving patients in various global markets who depend on this medication.

Dr Reddys Laboratories has announced ambitious science-based Net Zero climate targets, positioning itself as a sustainability leader in India's pharmaceutical sector. The company has set comprehensive emissions reduction goals approved by the Science Based Targets initiative (SBTi), demonstrating its commitment to environmental stewardship and climate action.

Net Zero Commitment and Timeline

Dr Reddys Laboratories commits to achieving Net Zero greenhouse gas emissions across its entire value chain by FY2045. This makes the company the first Indian pharmaceutical organization to commit to a science-based Net Zero target by this timeline, setting a benchmark for the industry.

The company has established both near-term and long-term targets using FY2023 as the baseline year:

Strategic Evolution and Framework Alignment

This announcement represents an evolution of the company's climate commitments. In October 2020, Dr Reddys initially announced near-term SBTi targets. Based on current progress and continued commitment to sustainability, the company has now revised its goals to Net Zero targets, aligning with the latest SBTi Framework requirements.

The revised targets reflect both enhanced ambition and accountability toward environmental protection while maintaining alignment with global climate goals.

Current Progress and Operational Achievements

Dr Reddys has demonstrated tangible progress in its climate actions. The company aims to achieve coal-and furnace oil-free operations by the end of FY26, representing a significant milestone in reducing carbon-intensive energy sources.

Additionally, 68.00% of the company's power in FY25 is expected to be sourced from renewable energy sources, showcasing the practical implementation of its climate commitments and the measurable impact of its sustainability initiatives.

Leadership Perspective

Sanjay Sharma, Global Head Operations and Chief Human Resource Officer at Dr Reddys Laboratories, emphasized the company's forward-looking vision and commitment to environmental responsibility. He highlighted that as an early adopter of sustainability practices, the company has consistently advanced through thoughtful and impactful climate actions.

The leadership stressed that these science-based targets guide the company's efforts to align with global climate goals while establishing industry benchmarks for the pharmaceutical sector.

Industry Leadership and Regulatory Compliance

This announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring proper disclosure to stakeholders. The company's commitment to science-based targets demonstrates its proactive approach to environmental governance and transparency in sustainability reporting.

Dr Reddys Laboratories continues to build on its history as an early adopter of sustainability and ESG actions, having released its first Sustainability Report in 2004, well ahead of industry standards.